WPP-201
AXP000233.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Sponsor
- Southwest Regional Wound Care Center
Names
| Name | Type | Source |
|---|---|---|
| WPP-201 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- bacteriophage cocktail of eight phages lytic for P. aeruginosa, S. aureus and E. coli
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00663091 | A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers | Completed | Phase 1 | 2006-09 | 2008-05 | 64 | Venous Leg Ulcers |
Recent changes
No changes recorded in its trials yet.
Notes
Phage preparation tested topically in venous leg ulcers in a randomised double-blind phase 1 trial, NCT00663091. Originator not taken from a primary source, so left empty. The registration describes WPP-201 as a pH-neutral polyvalent preparation of eight phages lytic for P. aeruginosa, S. aureus and E. coli.
How to cite
WPP-201 (AXP000233.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000233.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.